Papers by Hagop M. Kantarjian
Page 5 · newest first
- Common kinase mutations do not impact optimal molecular responses in core binding factor acute myeloid leukemia treated with fludarabine, cytarabine, and G‐CSF based regimensAmerican Journal of Hematology · 2022
- A retrospective study of cladribine and low‐dose cytarabine–based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemiaCancer · 2022
- A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignanciesCancer · 2022
- North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of needBlood · 2022
- TP53‐altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entityCancer · 2022
- Long-Term Outcomes of Acute Myeloid Leukemia Following Allogeneic Stem-Cell Transplantation after Decitabine and Venetoclax: Subgroup Analysis of a Phase II TrialBlood · 2022
- Updated Phase IIb Results of Venetoclax with FLAG-IDA in Relapsed or Refractory Acute Myeloid LeukemiaBlood · 2022
- Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLBlood Advances · 2022
- Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemiaBlood Cancer Journal · 2022
- A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLLBlood Advances · 2022
- TP53 -Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future DirectionsCancer Discovery · 2022
- Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypesAmerican Journal of Hematology · 2022
- Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemiaAmerican Journal of Hematology · 2022
- Postremission cytopenia management in patients with acute myeloid leukemia treated with venetoclax and azacitidine in VIALE‐AAmerican Journal of Hematology · 2022
- Retrospective comparison of survival and responses to Fludarabine, Cytarabine, GCSF (FLAG) in combination with gemtuzumab ozogamicin (GO) or Idarubicin (IDA) in patients with newly diagnosed core binding factor (CBF) acute myelogenous leukemia: MD Anderson experience in 174 patientsAmerican Journal of Hematology · 2022
- Contemporary outcomes in IDH ‐mutated acute myeloid leukemia: The impact of co‐occurring NPM1 mutations and venetoclax‐based treatmentAmerican Journal of Hematology · 2022
- Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndromeBlood Advances · 2022
- Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysisAmerican Journal of Hematology · 2022
- Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemiaAmerican Journal of Hematology · 2022
- Low-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDSNEJM Evidence · 2022
- High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significanceLeukemia · 2022
- The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysisBlood · 2022
- Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directionsAmerican Journal of Hematology · 2022
- Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free RegimensJAMA Oncology · 2022
- Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell NeoplasmJournal of Clinical Oncology · 2022
- Impact of SF3B1 mutation in myelofibrosisLeukemia & lymphoma/Leukemia and lymphoma · 2022
- Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoringAmerican Journal of Hematology · 2022
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic NeoplasmsLeukemia · 2022
- Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10⁻⁴ and higherAmerican Journal of Hematology · 2022
- Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaJournal of Clinical Oncology · 2022
- Results of a phase 1 trial of azacitidine with venetoclax in relapsed/refractory higher-risk myelodysplastic syndrome (MDS).Journal of Clinical Oncology · 2022
- A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.Journal of Clinical Oncology · 2022
- Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial.Journal of Clinical Oncology · 2022
- Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemiaAmerican Journal of Hematology · 2022
- Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemiaAmerican Journal of Hematology · 2022
- TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysisAmerican Journal of Hematology · 2022
- Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasmsBlood · 2022
- Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AMLBlood Cancer Journal · 2022
- Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cellsNature Communications · 2022
- Time to First Subsequent Salvage Therapy in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia Treated With Inotuzumab Ozogamicin in the Phase III INO-VATE TrialClinical Lymphoma Myeloma & Leukemia · 2022
- Pneumonitis after immune checkpoint inhibitor therapies in patients with acute myeloid leukemia: A retrospective cohort studyCancer · 2022
- Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trialsAmerican Journal of Hematology · 2022
- Prediction of survival with intensive chemotherapy in acute myeloid leukemiaAmerican Journal of Hematology · 2022
- Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitorsAmerican Journal of Hematology · 2022
- Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomabAmerican Journal of Hematology · 2022
- Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitorsLeukemia & lymphoma/Leukemia and lymphoma · 2022
- Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALLLeukemia · 2022
- Time to blur the blast boundariesCancer · 2022
- Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposureJournal of Hematology & Oncology · 2022
- Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapyBlood Cancer Journal · 2022